Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
25Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06094842CT.gov Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Receptor-Engineered T-Cells (this asset) | Fred Hutchinson Cancer Center | P1 | C · 39 |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Prednisone | Mayo Clinic | P4 | BBB |
| Enzalutamide | Pfizer | P4 | BBB |
| Degarelix | Baptist Health South Florida | P3 | BBB |
| Abiraterone | Mayo Clinic | P4 | BBB |
| Docetaxel | Alliance for Clinical Trials in Oncology | P3 | BB |
| Goserelin | Mayo Clinic | P3 | BB |
| Fludeoxyglucose | Jonsson Comprehensive Cancer Center | P2/3 | BB |
+41 more in the Prostate Carcinoma cohort
Other indications for T-Cell Receptor-Engineered T-Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Small Cell Carcinoma | — | P1 | CC · 40 |
| Prostate Cancer | — | P1 | CC · 40 |
| Metastatic Malignant Neoplasm | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. T-Cell Receptor-Engineered T-Cells in Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/t-cell-receptor-engineered-t-cells-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →